Why the study?
TMEM16A is a proposed therapeutic target for conditions such as hypertension, asthma, and cystic fibrosis, but its pharmacology remains poorly understood.
The cryo-EM structure of TMEM16A in complex with 1PBC reveals the mechanism of open-channel block, providing a structural basis for designing new modulators.
Reveals TMEM16A inhibition pocket; extends mechanistic insight but leaves open clinical translation in hypertension.
TMEM16A, a calcium-activated chloride channel involved in multiple cellular processes, is a proposed target for diseases such as hypertension, asthma, and cystic fibrosis. Despite these therapeutic promises, its pharmacology remains poorly understood. Here, we present a cryo-EM structure of TMEM16A in complex with the channel blocker 1PBC and a detailed functional analysis of its inhibition mechanism. A pocket located external to the neck region of the hourglass-shaped pore is responsible for open-channel block by 1PBC and presumably also by its structural analogs. The binding of the blocker stabilizes an open-like conformation of the channel that involves a rearrangement of several pore helices. The expansion of the outer pore enhances blocker sensitivity and enables 1PBC to bind at a site within the transmembrane electric field. Our results define the mechanism of inhibition and gating and will facilitate the design of new, potent TMEM16A modulators.
No takes yet. Share an insight, caveat, or question.
Dutzler et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: